Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer

Liver Cancer Clinical Trial

Official title:

A Non-Randomized Phase II Study of Sequential Irinotecan (CPT-11) And Flavopiridol In Patients With Advanced Hepatoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00087282
• Other study ID #: CDR0000373877
• Secondary ID: MSKCC-04038NCI-6
• Status: Completed
• Phase: Phase 2
• First received: July 8, 2004
• Last updated: June 21, 2013
• Start date: June 2004
• Est. completion date: July 2006

Study information

• Verified date: May 2005
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as irinotecan and flavopiridol, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving irinotecan together with flavopiridol works in treating patients with advanced liver cancer.

Description:

OBJECTIVES:

Primary

• Determine the time to progression in patients with advanced hepatocellular carcinoma treated with irinotecan and flavopiridol.

Secondary

• Determine the response rate and overall survival in patients treated with this regimen.

• Determine the toxicity of this regimen in these patients.

OUTLINE: This is an open-label, non-randomized study.

Patients receive irinotecan IV over 30 minutes and flavopiridol IV over 1 hour on days 1, 8, 15, and 22. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 16-32 patients will be accrued for this study within 2 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: July 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed hepatocellular carcinoma

• Advanced disease

• Measurable disease

• At least 1 unidimensionally measurable lesion = 20 mm by conventional techniques OR = 10 mm by spiral CT scan

• Prior local therapy (e.g., surgery, hepatic arterial embolization, radiofrequency ablation, or cryoablation) allowed provided therapy was completed = 8 weeks before study entry AND = 1 of the following conditions are met:

• Target lesion was not subjected to local therapy

• 25% increase in the size of target lesion within the field of prior local therapy

• Lesions treated with external beam radiotherapy are not acceptable as target lesions

• Child-Pugh class A or B status if liver cirrhosis is present

• Score 7 or 8 only

• No known brain metastases

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• Karnofsky 70-100%

Life expectancy

• Not specified

Hematopoietic

• Absolute neutrophil count = 1,500/mm^3

• Platelet count = 75,000/mm^3

• WBC = 3,000/mm^3

Hepatic

• See Disease Characteristics

• AST and ALT = 2.5 times upper limit of normal

• Bilirubin = 1.5 mg/dL

Renal

• Creatinine normal OR

• Creatinine clearance = 60 mL/min

Cardiovascular

• No symptomatic congestive heart failure

• No unstable angina pectoris

• No deep vein thrombosis within the past 6 months

• Patients maintained on anticoagulation therapy for an event that occurred more than 6 months ago are eligible

• No myocardial infarction within the past 6 months

• No cardiac arrhythmia within the past 6 months

• Rate-controlled atrial fibrillation allowed if stable for at least 6 months

Pulmonary

• No pulmonary embolus within the past 6 months

• Patients maintained on anticoagulation therapy for an event that occurred more than 6 months ago are eligible

Other

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception during and for 3 months after study participation

• No prior allergic reaction attributed to compounds of similar chemical or biological composition to flavopiridol or irinotecan

• No clinically significant gastrointestinal bleeding requiring hospitalization within the past month

• No active or ongoing infection

• No psychiatric illness or social situation that would preclude study compliance

• No other uncontrolled illness

• No other malignancy within the past 3 years except carcinoma in situ of the cervix, adequately treated basal cell skin cancer, or superficial bladder tumors [Ta, Tis, or T1]

PRIOR CONCURRENT THERAPY:

Biologic therapy

• No prior systemic biologic therapy

Chemotherapy

• No prior systemic chemotherapy for hepatocellular carcinoma

• No other concurrent chemotherapy

Endocrine therapy

• Not specified

Radiotherapy

• See Disease Characteristics

Surgery

• See Disease Characteristics

• No prior organ allograft

Other

• No concurrent combination antiretroviral therapy for HIV-positive patients

• No concurrent vitamins, antioxidants, or herbal preparations and supplements

• Single-tablet multivitamin allowed

• No other concurrent investigational agents

• No other concurrent anticancer agents or therapies

Study Design

Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Liver Cancer
• Liver Neoplasms

Intervention

Drug:
• alvocidib

• irinotecan hydrochloride

Locations

Country	Name	City	State
United States	Memorial Sloan-Kettering Cancer Center	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States,